Adamis Pharmaceuticals

Its specialty pharmaceutical division currently has four products in its pipeline including the Epinephrine Injection Pre-filled Syringe (PFS) for use in the emergency treatment of anaphylaxis, APC-1000 and APC-5000 (Dry Powder Inhaler) for the treatment of asthma and chronic obstructive pulmonary disease (COPD), and APC-3000, a hydrofluoroalkane (HFA) inhaled nasal steroid product for the treatment of allergic rhinitis. This division’s focus is to create low cost therapeutic alternatives to existing treatments in large markets. Adamis will pursue 505(b)(2) regulatory approval filings in order to minimize costs and shorten the time to market in this division. Within its biotechnology division, the Company has four products under development include TeloB-VAX, a novel cell-based therapeutic cancer vaccine for prostate cancer and three drugs, APC-100, APC-200, and APC-300, for the treatment of prostate cancer.
Type
Public
HQ
San Diego, US
Founded
2006
Employees
15 (est)+16%
Adamis Pharmaceuticals was founded in 2006 and is headquartered in San Diego, US

Key People at Adamis Pharmaceuticals

Robert O. Hopkins

Robert O. Hopkins

CFO
Dennis J. Carlo

Dennis J. Carlo

CEO

Adamis Pharmaceuticals Locations

San Diego, US

Adamis Pharmaceuticals Metrics

Adamis Pharmaceuticals Summary

Market capitalization

$62.6 M

Closing share price

$2.8
Adamis Pharmaceuticals's latest market capitalization is $62.6 M.

Adamis Pharmaceuticals Market Value History

15% of current employees of Adamis Pharmaceuticals are female and 85% are male.

Adamis Pharmaceuticals News

Adamis Pharmaceuticals Company Life

You may also be interested in